JP Morgan Chase
BLTE

JP Morgan Chase’s Belite Bio BLTE Stock Holding History

JP Morgan Chase’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$448 Hold
3
– – ﹤0.01% 7187
2025
Q4 		$480 Sell
3
-9,806
-100% -$1.16M ﹤0.01% 7084
2025
Q3 		$726K Buy
9,809
+3,052
+45% +$200K ﹤0.01% 4813
2025
Q2 		$390K Sell
6,757
-1,405
-17% -$85.7K ﹤0.01% 4905
2025
Q1 		$540K Sell
8,162
-6,474
-44% -$390K ﹤0.01% 4717
2024
Q4 		$924K Buy
14,636
+8,280
+130% +$546K ﹤0.01% 4696
2024
Q3 		$298K Buy
6,356
+6,268
+7,123% +$304K ﹤0.01% 5208
2024
Q2 		$4.02K Sell
88
-570
-87% -$24.7K ﹤0.01% 6424
2024
Q1 		$25.2K Sell
658
-13,609
-95% -$609K ﹤0.01% 6163
2023
Q4 		$653K Buy
+14,267
New +$548K ﹤0.01% 4619
2022
Q4 		– Sell
-7,400
Closed -$250K – 6554
2022
Q3 		$250K Buy
+7,400
New +$256K ﹤0.01% 4840

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase's BLTE Position: Q1 2026 in Review

JP Morgan Chase held its Belite Bio (BLTE) position steady in Q1 2026 at 3 shares worth $448. The position accounts for ﹤0.01% of the portfolio, ranked #7187.

JP Morgan Chase first reported a position in BLTE in Q3 2022 and has held it in 11 quarters since. The position peaked at $924K in Q4 2024. 75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • JP Morgan Chase held 3 shares of Belite Bio worth $448 as of Q1 2026.
  • JP Morgan Chase left its Belite Bio share count unchanged in Q1 2026.
  • Belite Bio made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7187 holding.
  • JP Morgan Chase first reported a position in Belite Bio in Q3 2022 and has held it in 11 quarters since.
  • JP Morgan Chase's Belite Bio position peaked at $924K in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.